Adverse symptomatology and suicide associated with the use of methylenedioxymethamphetamine (MDMA; "Ecstasy").
Cohen
R S
RS
D000293:Adolescent; D000328:Adult; D003131:Combined Modality Therapy; D003866:Depressive Disorder / Q000139:chemically induced / Q000523:psychology / Q000534:rehabilitation; D005260:Female; D006213:Hallucinogens / Q000008:administration & dosage / Q000009:adverse effects*; D006801:Humans; D008297:Male; D018817:N-Methyl-3,4-methylenedioxyamphetamine / Q000008:administration & dosage / Q000009:adverse effects*; D019966:Substance-Related Disorders / Q000523:psychology* / Q000534:rehabilitation; D013405:Suicide / Q000523:psychology*
D006213:Hallucinogens; D018817:N-Methyl-3,4-methylenedioxyamphetamine